laboratory, and therefore it could not be determined if she was an optimal responder. In routine testing done 21 months after the first dose, anti-HB s was no longer detectable (ie, <2.1 S/N units) and HB s Ag had developed. The technician had no fatigue, malaise, arthralgia, jaundice, or abdominal pain. At work she had rotated through the separate unit for dialysis patients who are known chronic carriers of hepatitis B virus (HBV), but she was unaware of percutaneous or mucous membrane exposure to blood or secretions. Moreover, she denied nonwork-related exposure to any of the known risk factors for HBV infection. Her physical examination was and continues to be normal. Serum transaminase levels were elevated for 3 months (peak SGPT level, 688 mlU/ ml) before r e t u r n i n g to n o r m a l . HB s Ag persisted for 5 months before disappearing coincidentally with the return of anti-HB s (4 S/N units).
Although vaccine-induced antiHBs is protective against HBV infection, it is unclear what minimum level is necessary for protection and what the duration of protection might be. Recent studies suggest that peak postvaccination anti-HB s levels are lower in individuals injected in the buttock c o m p a r e d to individuals injected in the arm. 9 It is known that the peak level of antibody following vaccination correlates with the duration of detectable antibody. 7 Vaccinated individuals might be protected even after their anti-HBs has dropped to u n d e t e c t a b l e levels, since on exposure to HBV an anamnestic response may prevent infection or limit it to seroconversion to hepatitis B core antigen only. However, such an anamnestic response may be lacking or insufficient to prevent HBV infection in those with a suboptimal anti-HB S vaccine response. 8 The duration of protection can be determined only by observing when breakthrough infections such as this begin to occur. The paucity of known similar cases suggests that breakthrough infections with HB s Ag and elevated t r a n s a m i n a s e levels are uncommon or unrecognized. Followup of several vaccine trial cohorts is underway to examine the relation between degree of response and duration of protection. 7 and elevated levels of transaminases among healthy, presumed immuno-•O competent vaccine recipients who had * developed an o p t i m a l a n t i b o d y 4^ response (ie, >10 S/N units by radioimmunoassay) to the surface antigen 1 (anti-HBJ. [1] [2] [3] [4] [5] [6] [7] However, data from follow-up of vaccinated h o m o s e x u a l males have revealed that HB s Ag developed and transaminases became * elevated in some whose maximum H postvaccination anti-HB s response was * s u b o p t i m a l (ie, 2.1 to < 1 0 S/N units). 7 
